Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

Nutrition Research

Volumn 34, Issue 10, 2014, Pages 837-843

  Faghihzadeh, Forouzan ^a,b   Adibi, Peyman ^b   Rafiei, Rahmatollah ^c   Hekmatdoost, Azita ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Clinical trial; Fatty liver; Inflammation; NAFLD; Resveratrol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PLACEBO; RESVERATROL; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; KRT18 PROTEIN, HUMAN; PLANT EXTRACT; POLYPHENOL; STILBENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; APOPTOSIS; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; HIP CIRCUMFERENCE; HUMAN; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LIVER CELL; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ANTHROPOMETRY; BLOOD; DIET; DRUG EFFECTS; ENZYMOLOGY; EXERCISE; FATTY LIVER; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHYTOTHERAPY;

ADULT; ALANINE TRANSAMINASE; ANTHROPOMETRY; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CYTOKINES; DIET; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; EXERCISE; FATTY LIVER; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KERATIN-18; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYTOTHERAPY; PLANT EXTRACTS; POLYPHENOLS; STILBENES;

EID: 84922460686     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2014.09.005     Document Type: Article

References (40)

1. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. Aliment Pharmacol Ther 2012, 36:815-823.
2. Petta S., Muratore C., Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009, 41:615-625.
3. Arendt B.M., Allard J.P. Effect of Atorvastatin, Vitamin E and C on Nonalcoholic Fatty Liver Disease: Is the Combination Required&quest. Am J Gastroenterol 2011, 106:78-80.
4. Duvnjak M., Tomasic V., Gomercic M., Smircic Duvnjak L., Barsic N., Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009, 60:57-66.
5. Targher G., Bellis A., Fornengo P., Ciaravella F., Pichiri I., Cavallo Perin P., et al. Prevention and treatment of nonalcoholic fatty liver disease. Dig Liver Dis 2010, 42:331-340.
6. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
7. Gonciarz M., Gonciarz Z., Bielanski W., Mularczyk A., Konturek P., Brzozowski T., et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012, 63(1):35-40.
8. Elias M.C., Parise E.R., Carvalho Ld, Szejnfeld D., Netto J.P. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 2010, 26:1094-1099.
9. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
10. Ghaemi A., Taleban F.A., Hekmatdoost A., Rafiei A., Hosseini V., Amiri Z., et al. How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?. Hepat Mon 2013, 13:e15227.
11. Eslamparast T., Poustchi H., Zamani F., Sharafkhah M., Malekzadeh R., Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014, 99:535-542.
12. Askari F., Rashidkhani B., Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res 2014, 34:143-148.
13. Luther D.J., Ohanyan V., Shamhart P.E., Hodnichak C.M., Sisakian H., Booth T.D., et al. Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs 2011, 29:380-391.
14. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
15. Shankar S., Singh G., Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 2007, 12:4839-4854.
16. Saiko P., Szakmary A., Jaeger W., Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?. Mutat Res 2008, 658:68-94.
17. Shakibaei M., Harikumar K.B., Aggarwal B.B. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009, 53:115-128.
18. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
19. Muriel P., Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol 2008, 28:93-103.
20. Schmatz R., Perreira L.B., Stefanello N., Mazzanti C., Spanevello R., Gutierres J., et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie 2012, 94:374-383.
21. Initiative NOE The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity 2000.
22. WHO STEPwise approach to surveillance (STEPS) 2012, World Health Organization, Geneva.
23. Ghaffarpour M., Houshiar-Rad A., Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods 1999, 1-40. Nashre Olume Keshavarzy, Tehran.
24. Ainsworth B.E., Haskell W.L., Whitt M.C., Irwin M.L., Swartz A.M., Strath S.J., et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000, 32:S498-S504.
25. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., Garcia-Urkia N., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008, 8:40.
26. Li L., Hai J., Li Z., Zhang Y., Peng H., Li K., et al. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014, 63:166-173.
27. Choi Y.J., Suh H.R., Yoon Y., Lee K.J., Kim D.G., Kim S., et al. Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res 2014, 37(9):1169-1176.
28. Poulsen M.M., Larsen J.O., Hamilton-Dutoit S., Clasen B.F., Jessen N., Paulsen S.K., et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a highfat diet. Nutr Res 2012, 32:701-708.
29. Yang S.J., Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 2014, 63(5):693-701.
30. Gómez-Zorita S., Fernández-Quintela A., MacArulla M.T., Aguirre L., Hijona E., Bujanda L., et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012, 107:202-210.
31. Qiao Y., Sun J., Xia S., Tang X., Shi Y., Le G. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct 2014, 5(6):1241-1249.
32. Timmers S., Konings E., Bilet L., Houtkooper R.H., Van De Weijer T., Goossens G.H., et al. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14:612-622.
33. Bo S., Ciccone G., Castiglione A., Gambino R., De Michieli F., Villois P., et al. Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. Curr Med Chem 2013, 20:1323-1331.
34. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012, 32:537-541.
35. Tomé-Carneiro J., Gonzálvez M., Larrosa M., Yáñez-Gascón M.J., García-Almagro F.J., Ruiz-Ros J.A., et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013, 27:37-48.
36. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S.I., Schechtman K.B., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012, 16:658-664.
37. Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O'Moore-Sullivan T.M., Lee P., et al. Resveratrol Does Not Benefit Patients with Non-alcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2014.
38. Crandall J.P., Oram V., Trandafirescu G., Reid M., Kishore P., Hawkins M., et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A: Biol Med Sci 2012, 67:1307-1312.
39. Tamimi T.I., Elgouhari H.M., Alkhouri N., Yerian L.M., Berk M.P., Lopez R., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011, 54:1224-1229.
40. Malekzadeh R., Poustchi H. Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon 2011, 11:157-158.